SCHEMBL1423790

SCHEMBL1423790

c1ccc(-c2ccc(OCc3cn4ccccc4n3)cc2)c(-c2ccncc2)c1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 7/20 0.65
▸ RAB9A P51151 7/20 0.65
▸ NPC1 O15118 6/20 0.65
▸ SMN1; SMN2 Q16637 5/20 0.65
▸ ALDH1A1 P00352 4/20 0.61
▸ LMNA P02545 2/20 0.61
▸ PDE10A Q9Y233 4/20 0.60
▸ MAPK1 P28482 2/20 0.49
▸ PKM P14618 2/20 0.49
▸ MAPT P10636 3/20 0.48
▸ POLB P06746 1/20 0.48
▸ NFKB1 P19838 1/20 0.47
▸ NFKB2 Q00653 1/20 0.47
▸ RELA Q04206 1/20 0.47
▸ GAA P10253 1/20 0.46
▸ TDP1 Q9NUW8 2/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ LGALS3 P17931 1/20 0.46
▸ PDE4D Q08499 1/20 0.46
▸ HPGD P15428 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11427962 0.88 KDM4E (0.72) KDM4ERAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL4791752 0.86 PDE10A (0.67) PDE10ALGALS3PDE4D
SCHEMBL4767374 0.86 PDE10A (0.59) KDM4ERAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL4861110 0.82 PDE10A (0.69) KDM4ERAB9ANPC1SMN1; SMN2PDE10A
SCHEMBL17694678 0.81 KDM4E (0.78) KDM4ERAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL4726835 0.79 NPC1 (0.75) KDM4ERAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL14653881 0.76 NPC1 (0.59) KDM4ERAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL12970288 0.75 NPC1 (0.57) KDM4ERAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL23488101 0.75 KDM4E (1.00) KDM4ERAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL3476282 0.74 KDM4E (0.67) KDM4ERAB9ANPC1SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110224204-A1 DI-SUBSTITUTED PHENYL COMPOUNDS ENVIVO PHARMACEUTICALS, INC. 2011-09-15 — — US disclosed
EP-2297131-A2 DI-SUBSTITUTED PHENYL COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS Envivo Pharmaceuticals, Inc. (US) 2011-03-23 — — EP disclosed
WO-2009158467-A2 DI-SUBSTITUTED PHENYL COMPOUNDS ENVIVO PHARMACEUTICALS, INC. (US) 2009-12-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224204-A1 DI-SUBSTITUTED PHENYL COMPOUNDS PDE10A, PDE1A, PDE12 KDM4E 1168/4885RAB9A 597/4885NPC1 2142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback